Metran (Metronidazole)

Metronidazole enters susceptible microorganisms and is reduced to nitro radical anions by bacterial ferredoxin proteins. These reactive species damage DNA and inhibit protein synthesis, leading to cell death in anaerobic bacteria and protozoa while sparing aerobic cells.

The appropriate dose of metronidazole is determined by the prescribing healthcare professional based on the specific infection, patient age, weight, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and the product label.

Safety of metronidazole during pregnancy or lactation depends on the trimester and clinical necessity. Healthcare providers weigh potential benefits against risks, and the drug may be used when clearly needed. Breastfeeding mothers should consult their physician, as small amounts can be excreted in milk.

To order Metran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Metronidazole is a first‑line nitroimidazole for many anaerobic and protozoal infections. Compared with alternatives such as tinidazole, it has a similar spectrum but a shorter half‑life, often requiring multiple daily doses. Choice of therapy depends on infection type, patient tolerance, drug interactions and local resistance patterns.

Metran should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Metran is administered orally, usually as tablets or a liquid suspension, and should be taken with or without food as directed by the prescriber. The full course should be completed even if symptoms improve, to ensure eradication of the infection.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as Stevens‑Johnson syndrome, and hepatic toxicity. Patients should seek immediate medical attention if they experience neurological symptoms, rash, or signs of liver dysfunction while on therapy.

Metronidazole is contraindicated in individuals with a known hypersensitivity to the drug or other nitroimidazoles. Caution is advised for patients with severe hepatic impairment, and it should be avoided in those who cannot abstain from alcohol during and shortly after treatment.